Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 1/2, Dose-finding and Dose Expansion Study of OSE-279, a PD-1 Blocking Monoclonal Antibody, in Subjects With Advanced Solid Tumors or Lymphomas

NCT05751798 is registered in ClinicalTrials.gov with OSE Immunotherapeutics as lead sponsor.

NCT NCT05751798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05751798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 1/2, Dose-finding and Dose Expansion Study of OSE-279, a PD-1 Blocking Monoclonal Antibody, in Subjects With Advanced Solid Tumors or Lymphomas
Lead sponsor
OSE Immunotherapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 20, 2022
Completion date
December 31, 2029
Enrollment
41 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, nsclc (non-small cell lung cancer), solid advanced tumor